ASCEnD Study
Cross-source consensus on ASCEnD Study from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Where it comes from
Other
Other
Highlighted claims
- The study is funded by the NIHR Health Technology Assessment programme. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- The trial was registered as ISRCTN63917405 on 23 November 2023. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- The ASCEnD study tests whether aripiprazole plus sertraline is clinically effective and cost-effective compared with quetiapine monotherapy in adults with bipolar depression. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
- Recruitment began in April 2024 after delays and is currently planned to end in August 2027. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol